These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16757419)

  • 1. Life-threatening motor neurotoxicity in association with bortezomib.
    Gupta S; Pagliuca A; Devereux S; Mufti GJ; Schey S
    Haematologica; 2006 Jul; 91(7):1001. PubMed ID: 16757419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
    Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
    J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
    Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
    J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
    Richardson P
    Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
    [No Abstract]   [Full Text] [Related]  

  • 6. Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
    Giaccone L; Sorasio R; Patriarca F; Mattei D; Montefusco V; Peccatori J; Carnevale-Schianca F; Petrucci MT; Milone G; Guidi S; Rotta M; Fanin R; Corradini P; Boccadoro M; Bruno B
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):497-9. PubMed ID: 17382258
    [No Abstract]   [Full Text] [Related]  

  • 7. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
    Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
    Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib: the subtle line between drug-induced peripheral neuropathy and post-herpetic neuralgia.
    Focosi D
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):E16-7. PubMed ID: 19717373
    [No Abstract]   [Full Text] [Related]  

  • 9. Bortezomib in multiple myeloma.
    Meisler AI
    N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib-induced inflammatory neuropathy.
    Saifee TA; Elliott KJ; Rabin N; Yong KL; D'Sa S; Brandner S; Lunn MP; Blake J; Reilly MM
    J Peripher Nerv Syst; 2010 Dec; 15(4):366-8. PubMed ID: 21199108
    [No Abstract]   [Full Text] [Related]  

  • 11. Bortezomib-induced neurogenic bladder in patients with multiple myeloma.
    Shimura K; Shimazaki C; Taniguchi K; Inaba T; Horiike S; Taniwaki M
    Ann Hematol; 2009 Apr; 88(4):383-4. PubMed ID: 18836719
    [No Abstract]   [Full Text] [Related]  

  • 12. Immune-mediated neuropathies in myeloma patients treated with bortezomib.
    Ravaglia S; Corso A; Piccolo G; Lozza A; Alfonsi E; Mangiacavalli S; Varettoni M; Zappasodi P; Moglia A; Lazzarino M; Costa A
    Clin Neurophysiol; 2008 Nov; 119(11):2507-12. PubMed ID: 18829381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From bench to bedside: a case of rapid reversal of bortezomib-induced neuropathic pain by the TRPM8 activator, menthol.
    Colvin LA; Johnson PR; Mitchell R; Fleetwood-Walker SM; Fallon M
    J Clin Oncol; 2008 Sep; 26(27):4519-20. PubMed ID: 18802169
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 15. Unexpected cardiotoxicity in haematological bortezomib treated patients.
    Enrico O; Gabriele B; Nadia C; Sara G; Daniele V; Giulia C; Antonio S; Mario P
    Br J Haematol; 2007 Aug; 138(3):396-7. PubMed ID: 17561972
    [No Abstract]   [Full Text] [Related]  

  • 16. Cutaneous leucoclastic vasculitis (LV) following bortezomib therapy in a myeloma patient; association with pro-inflammatory cytokines.
    Min CK; Lee S; Kim YJ; Eom KS; Lee JW; Min WS; Kim CC; Cho CS; Park G
    Eur J Haematol; 2006 Mar; 76(3):265-8. PubMed ID: 16451401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
    Berkowitz A; Walker S
    Clin J Oncol Nurs; 2012 Feb; 16(1):86-9. PubMed ID: 22297012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology].
    Gotoh A; Ohyashiki K; Oshimi K; Usui N; Hotta T; Dan K; Ikeda Y; ;
    Rinsho Ketsueki; 2006 Dec; 47(12):1521-7. PubMed ID: 17233470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variation associated with bortezomib-induced peripheral neuropathy.
    Favis R; Sun Y; van de Velde H; Broderick E; Levey L; Meyers M; Mulligan G; Harousseau JL; Richardson PG; Ricci DS
    Pharmacogenet Genomics; 2011 Mar; 21(3):121-9. PubMed ID: 21228734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib in multiple myeloma.
    Mateos MV; San Miguel JF
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.